Walter Taal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5043632/publications.pdf

Version: 2024-02-01

43 papers	4,120 citations	304743 22 h-index	254184 43 g-index
47 all docs	47 docs citations	47 times ranked	4951 citing authors

#	Article	IF	Citations
1	The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. Neuro-Oncology, 2022, 24, 429-441.	1.2	7
2	Attention and Motor Learning in Adult Patients with Neurofibromatosis Type 1. Journal of Attention Disorders, 2022, 26, 563-572.	2.6	6
3	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. Neuro-Oncology, 2022, 24, 326-328.	1.2	5
4	Diagnostic value of 18F-FDG PET-CT in detecting malignant peripheral nerve sheath tumors among adult and pediatric neurofibromatosis type 1 patients. Journal of Neuro-Oncology, 2022, 156, 559-567.	2.9	3
5	The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology Advances, 2022, 4, vdac032.	0.7	1
6	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. Neuro-Oncology Practice, 2022, 9, 310-316.	1.6	7
7	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
8	A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis. Neuro-Oncology, 2021, 23, 557-571.	1.2	8
9	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	7.7	32
10	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34
11	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 1 0.784314 rgBT /Ov Oncology, The, 2021, 22, 813-823.	10.7	132
12	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. Neuro-Oncology Advances, 2021, 3, vdab145.	0.7	3
13	Motor cortical excitability and plasticity in patients with neurofibromatosis type 1. Clinical Neurophysiology, 2020, 131, 2673-2681.	1.5	5
14	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
15	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 2927.	3.3	8
16	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. Neurology, 2019, 92, e2754-e2763.	1.1	9
17	Worries and needs of adults and parents of adults with neurofibromatosis type 1. American Journal of Medical Genetics, Part A, 2018, 176, 1150-1160.	1.2	32
18	Clinical management of spinal metastasesâ€"The Dutch national guideline. European Journal of Cancer, 2018, 104, 81-90.	2.8	48

#	Article	IF	Citations
19	The Dutch national guideline on metastases and hematological malignancies localized within the spine; a multidisciplinary collaboration towards timely and proactive management. Cancer Treatment Reviews, 2018, 69, 29-38.	7.7	19
20	Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neuro-Oncology, 2017, 19, now194.	1.2	45
21	Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumabâ€"a report from the BELOB trial. Neuro-Oncology, 2017, 19, 853-861.	1.2	34
22	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
23	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	27.0	670
24	Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. PLoS ONE, 2017, 12, e0183155.	2.5	12
25	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 2016, 76, 525-534.	0.9	93
26	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 2015, 51, 1321-1330.	2.8	45
27	Chemotherapy in glioma. CNS Oncology, 2015, 4, 179-192.	3.0	58
28	Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. Journal of Neuro-Oncology, 2015, 121, 365-372.	2.9	31
29	Are we done with dose-intense temozolomide in recurrent glioblastoma?. Neuro-Oncology, 2014, 16, 1161-1163.	1.2	11
30	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology, The, 2014, 15, 943-953.	10.7	639
31	Bevacizumab alone or in combination with chemotherapy in glioblastomas?â€"Authors' reply. Lancet Oncology, The, 2014, 15, e473-e474.	10.7	3
32	A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.2	20
33	Dose dense 1Âweek on/1Âweek off temozolomide in recurrent glioma: a retrospective study. Journal of Neuro-Oncology, 2012, 108, 195-200.	2.9	34
34	Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Supportive Care in Cancer, 2012, 20, 1639-1647.	2.2	10
35	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. Journal of Neuro-Oncology, 2011, 101, 405-417.	2.9	25
36	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro-Oncology, 2011, 13, 235-241.	1.2	60

#	Article	IF	Citations
37	Incidence of early pseudoâ€progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer, 2008, 113, 405-410.	4.1	403
38	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncology, The, 2008, 9, 453-461.	10.7	990
39	Is motor inhibition during laughter due to emotional or respiratory influences?. Psychophysiology, 2004, 41, 254-258.	2.4	26
40	A woman with multiple sclerosis and pink saliva. Lancet Neurology, The, 2003, 2, 254-255.	10.2	5
41	GABA and glycine frequently colocalize in terminals on cat spinal motoneurons. NeuroReport, 1994, 5, 2225-2228.	1.2	93
42	Rare CNS tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas and intracranial germ cell tumors. Neuro-Oncology Advances, 0, , .	0.7	0
43	Evaluation of an online tool about the expected course of disease for glioblastoma patients â€“ a qualitative study. Neuro-Oncology Practice, 0, , .	1.6	0